Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the…
Read More
The Future of Patient Adherence Hinges on Flexible, Engaging, and Affordable Health Technologies
The pharmaceutical, biotech, and medtech industries are witnessing an unprecedented surge in innovations, offering patients access to treatments previously considered…
Read More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Bolster Immunology Pipeline
AbbVie has announced a landmark $10.9 billion acquisition of Apogee Therapeutics, a strategic move poised to significantly fortify the biopharmaceutical…
Read More
LG AI Research and D&D Pharmatech Forge Landmark Partnership to Revolutionize Oral Peptide Drug Delivery Through Artificial Intelligence
LG AI Research and D&D Pharmatech have officially inked a pivotal agreement, signaling a new era in pharmaceutical innovation with…
Read More
Semiconductor Hiring Cools in April 2026 After Q1 Surge, Signaling Shifting Investment Priorities
Global semiconductor job postings experienced a notable decline of 6.58% month-on-month in April 2026, settling at 30,956. This marks the…
Read More
Radiopharmaceuticals Ascend: ASCO 2026 Highlights Evolving Cancer Treatment Landscape
The burgeoning field of radiopharmaceuticals, propelled by the success of treatments like Novartis’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan), is…
Read More
GLP-1 Blockbusters Propel Pharma R&D Returns to 7%, Masking Broader Productivity Challenges, Deloitte Report Reveals
After a prolonged period where growth remained uneven in the wake of global disruptions, a pivotal metric for biopharma research…
Read More
Biogen Acquires RayThera for Up to $1 Billion to Bolster Immunology Pipeline
Biogen Inc. has announced a definitive agreement to acquire RayThera, a privately held biotechnology company focused on developing small-molecule therapies…
Read More
CNPV: A gamechanger for the pharma industry or simply more chaos?
The U.S. Food and Drug Administration (FDA) launched its Commissioner’s National Priority Voucher (CNPV) pilot program in June 2025, an…
Read More
Voro Therapeutics and Alloy Therapeutics Forge Strategic Partnership to Revolutionize Tumour-Selective T-Cell Engager Therapies
Voro Therapeutics and Alloy Therapeutics have announced a significant strategic research partnership aimed at developing a new generation of masked…
Read MoreYOU MAY HAVE MISSED
